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Objectives: Changes in hemostasis after off-pump coronary artery bypass grafting are
still being discussed. There is a lack of information about platelet activity and aspirin
efficacy after coronary artery bypass grafting. The aim of this study was to assess and
compare platelet activity and aspirin efficacy early and late after off-pump and
on-pump coronary artery bypass grafting.
Methods: Eighty patients were enrolled in a prospective randomized study. Platelet
activity was determined based on membrane expression of antigen CD62P (P-selec-
tin) by means of flow cytometric analysis. Aspirin efficacy was assessed by using
arachidonic acid–induced platelet aggregation. Blood samples were collected before
the operation, immediately postoperatively, and on days 1, 2, 5, and 30.
Results: In the off-pump group expression of P-selectin was markedly increased in
comparison with preoperative values, with a maximum difference observed on day
2 (153%, P 5 .02), and it was significantly higher compared with that seen in the
on-pump group on days 2 and 5 (153% vs 14%, P 5 .004, and 120% vs 216%,
P 5 .005). On day 30, P-selectin expression was similar both between the groups
and in comparison with the preoperative values. Arachidonic acid–induced platelet
aggregation was gradually decreasing until day 30, but on day 2, there was an unex-
pected increase in aggregation that was more expressed in the off-pump group.
Conclusions: The platelet activity is higher in the early postoperative period in off-
pump compared with on-pump coronary artery bypass grafting. The present aspirin
strategy seems to be insufficient in the early postoperative period, irrespective of
the surgical technique used.
C
oronary artery bypass grafting (CABG) performed with cardiopulmonary
bypass (CPB) is associated with hemostatic changes that can either lead to
early bleeding complications (postoperative bleeding) or, in contrast, to early
thrombotic complications (generation of microthrombi and CPB-related organ dys-
function). These conditions are caused in various ways by changes in coagulation
factors, fibrinolysis, and platelet dysfunction.1,2
Off-pumpCABG surgery has been established as a less-invasive alternative to con-
ventional CABG. Elimination of CPB leads to the reduction of hemostatic defects and
consequently to less postoperative bleeding and fewer requirements for blood trans-
fusion.3 However, several recent studies suggest that off-pump surgery could cause
a procoagulant state, which appears within the first postoperative days and could pos-
sibly contribute to early thrombotic complications and affect early venous graft
patency after off-pump CABG.4-7 Nevertheless, the described coagulation changes
are often limited only to plasma markers, and not much is known about platelets
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PAbbreviations and Acronyms
ACT 5 activated clotting time
CABG 5 coronary artery bypass grafting
CPB 5 cardiopulmonary bypass
FITC 5 fluorescein isothiocyanate
MI 5 myocardial infarction
PRP 5 platelet-rich plasma
and their activity in the first postoperative days after bypass
surgery.8-11 The significance of platelets early after CABG
is also supported by the fact that platelets play a key role in
the process of arterial thrombosis and also the fact that the in-
hibition of platelets by early administered aspirin has a clear
benefit against graft thrombosis and affects saphenous vein
graft patency.12 In spite of this, changes in early and late
platelet activity between off-pump and on-pump CABG
and aspirin efficacy after both types of surgical intervention
have not been thoroughly studied.
In the present prospective, randomized PRAGUE 11–
CABARET study, we evaluated the early and late postoper-
ative platelet activity between on-pump and off-pump CABG
and compared aspirin efficacy on inhibition of platelet aggre-
gation early and late after both types of operation.
Materials and Methods
Patient Enrollment
Eighty patients were randomized in a prospective study by using the
envelope method (n 5 40 for off-pump and n 5 40 for on-pump
CABG surgery). Informed consent was obtained from all partici-
pants before enrollment in the study. The study protocol has been
approved by the hospital ethics committee, and the study was per-
formed in accordance with the Declaration of Helsinki. Patients
were consecutively enrolled from May 2005 to December 2006.
Inclusion criteria for enrollment of patients in this study were as
follows: (1) indication for CABG surgery and (2) aspirin, heparin,
or low-molecular-weight heparin withdrawal more than 7 days
before the operation or clopidogrel withdrawal more than 14 days
before the operation. Exclusion criteria were as follows: (1) nonsta-
ble angina pectoris, (2) acute myocardial infarction (MI) less than 30
days before the operation, (3) percutaneous coronary intervention
less than 30 days before the operation, (4) stroke less than 6 months
before the operation, (5) concomitant operation (valvular or MAZE
procedure), (6) renal insufficiency (serum creatinine.120 mmol/L),
(7) liver disorder, or (8) platelet count of less than 150,000, pro-
thrombin time greater than 1.2 international normalized ratio
(INR), activated partial thromboplastin time test/control of greater
than 1.2, antithrombin III level of less than 80% or greater than
120%, and fibrinogen level of less than 2 or greater than 6 g/L.
Anesthetic and Surgical Technique
Fast-track anesthesia and off-pump and on-pump operations were
performed as described previously.13,14The Journal of ThoraHeparin and Protamine Management
In the on-pump group heparin was administered at an initial dose of
300 IU/kg to achieve an activated clotting time (ACT) of 480 sec-
onds. ACT was monitored every 30 minutes, and an additional hep-
arin bolus (5000 IU) was administered when ACT was less than 440
seconds.
In the off-pump group heparin was administered at an initial dose
of 150 IU/kg to achieve an ACT of more than 250 seconds. On com-
pletion of all anastomoses, the heparin effect was reversed with prot-
amine chloride. An empiric dose regimen of 300mg (in the on-pump
group) and 100 mg (in the off-pump group) was administered, and if
required, additional protamine was added to achieve an ACT of less
than 130 seconds at the end of the operation.
Perioperative and Postoperative Drug and Fluid
Management
In the perioperative period no antifibrinolytics (eg, aprotinin and tra-
nexamic acid) were used in either group. Crystalloid solutions and
5% albumin solution were administered during the procedure. A
red blood cell transfusion was administered when hemoglobin
decreased to less than 8.5 g/dL or hematocrit to less than 26%. In
the postoperative period a transfusion of fresh frozen plasma was
administered when chest drain bleeding increased to more than
150 mL/h or to more than 100 mL/h for 2 consecutive hours. The
red blood cell transfusion was administered according to similar cri-
teria mentioned above. The platelet transfusion concentrates could
be administered in the postoperative period when chest drain bleed-
ing increased to 200 mL/h for a consecutive 3 hours and platelet
count was less than 60,000/mm3. No other prohemostatic agents
were recommended according to the study protocol. Aspirin (200
mg) was readministered 12 hours after the procedure in both groups.
No additional antiaggregation or anticoagulation drugs (nonsteroi-
dal anti-inflammatory drugs or low-molecular-weight heparin)
were recommended during the first 5 days after the operation,
according to the study protocol.
Blood Sampling and Analyses
Blood samples were collected in the morning before the operation,
immediately after the operation (after skin closure, when the ACT
was ,130 seconds), and on postoperative days 1, 2, 5, and 30
(days 1, 2, 5, and 30). At the same time points, the samples for rou-
tine coagulation tests and biochemical analyses were collected.
Assays for Platelet Activity and Aspirin Efficacy
Platelet activity was determined by changes in the expression of the
platelet surface antigen CD62P (P-selectin) by using flow cytome-
try, and aspirin efficacy was determined by means of light transmis-
sion aggregometry after the addition of arachidonic acid (AA).15 At
the time points described above, 10 mL of venous blood was drawn
in 2 citrated (9NC sodium citrate 3.2%) vacutainers.
Flow cytometry. Platelet surface antigens were analyzed as
described previously.16 The sample was stored for 2 hours at 37C.
Supernatant was collected and platelet count was adjusted to 1003
109/L with homologous plasma and phosphate-buffered saline. Fifty
microliters of prepared sample was added to 50 mL of the stabilizer
Thrombofix (Immunotech, Beckman–Coulter Co). This mixture
was incubated for 2 hours at 37C. Twenty microliters of prepared
stabilized platelets were stained with the appropriate volume ofcic and Cardiovascular Surgery c Volume 136, Number 4 1055
Cardiopulmonary Support and Physiology Bednar et al
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nate (FITC)/CD41–phycoerythrin (Immunotech), CD62P-FITC/
CD42b (Immunotech), and isotype control IgG1-FITC/IgG1–
phycoerythrin (Immunotech). Stained samples were incubated for
10 minutes at room temperature, and 0.5 mL phosphate-buffered
saline was added and mixed. The flow cytometer was calibrated
with CYTO-COMP Reagent Kit (Immunotech) and the CYTO-
COMPCellKit (Immunotech). Analysiswas performed on anEPICS
XL flow cytometer (Beckman–Coulter, Inc). The gating strategy of
platelets was based on forward and side scatter and on the presence
of CD42b antigen. At least 10,000 platelets were analyzed in each
measurement. CD62P expression was determined as a percentage
of positive cells.
Aggregometry. Platelet-rich plasma (PRP) was prepared imme-
diately after blood collection by means of centrifugation of 5 mL
of anticoagulated blood at 150g for 10 minutes at room temperature.
PRPwas adjusted to a minimum platelet count of 150,000/mL. Plate-
let-poor plasma was obtained from the remaining sample by means
of centrifugation at 2500g for 20 minutes. Samples were assayed on
a PAP-4 Platelet Aggregation Profiler (BioBata Corp) with platelet-
poor plasma as 100% of transmittance. The transmittance was set to
0% after adding 200 mL of PRP. AA was added to each tube (the
final concentration of AA in the PRP was 0.5 mg/mL), and the
aggregation profiles were plotted (percentage transmittance vs
time). Platelet aggregability was calculated as total aggregation
(percentage at 5 minutes).17
Test reliability. The intra-assay coefficient of variation was 3.2%
6 2.4% for AA aggregability and 3.8%6 4.1% for CD62P. The in-
terassay (ie, intraindividual) variability was 8.9% 6 10.2% for AA
and 6.9%6 8.9% for CD62P in healthy non–aspirin-taking individ-
uals.
Power Calculation
We were unaware of previous data comparing the difference in
CD62P platelet membrane expression in patients after off-pump
and on-pump CABG surgery. Thus we based our power calculations
on the previous studies of comparing CD62P or other parameters of
platelet activity in patients after percutaneous coronary intervention.
We hypothesized a difference of two thirds of the standard deviation
in logged data. Therefore we needed data from a minimum of 34 pa-
tients in each group for a P value of less than .05 and a 1-b value of
greater than 0.8.
Statistical Analyses
Continuous variables were compared by using a 2-sample t test and
categorical variables by using a c2 test for independence in contin-
gency tables. The time courses of AA, CD62P, and platelets counts
were analyzed by means of analysis of variance for repeated mea-
sures. Correlations were evaluated by using the Spearman test.
The tests are carried out at the 5% significance level. The results
are presented as means 6 standard deviation or medians with
95% confidence intervals. Statistical analysis was performed with
SPSS for Win v.14 (SPSS, Inc).
Results
Patients’ Characteristics
Eighty patients were enrolled between May 2005 and De-
cember 2006, 40 in the off-pump and 40 in the on-pump1056 The Journal of Thoracic and Cardiovascular Surgery c Ocgroup. Clinical variables of these patients are reported in
Table 1. No significant differences between the groups
were observed for demographics, preoperative risk factors,
and medications. The basic preoperative hematologic para-
meters were also comparable (not shown). Perioperative and
postoperative data are summarized in Table 2. Number of
grafts, blood loss, heparin, and protamine doses were signif-
icantly higher in the on-pump group. The need for red blood
cell and fresh frozen plasma transfusions was similar in both
groups. In the on-pump group 2 patients received platelet
transfusions postoperatively. In the off-pump group one pa-
tient received clopidogrel postoperatively. No significant dif-
ferences in clinical outcome between groups were observed,
and none of the patients died. In 4 patients (2 in the on-pump
and 2 in the off-pump groups) there were signs of periopera-
tive or postoperative MI. In 1 patient MI developed in the
perioperative period, in 2 patients very early after admission
to the intensive care unit and in 1 patient (on-pump group)
after discharge from our department. There were no other
signs of thrombotic complications.
Platelet Activity and Aspirin Efficacy Studies
Seven patients mentioned above were excluded from the
analysis of platelet function (2 patients for platelet transfu-
sion, 4 patients for MI, and 1 patient for clopidogrel
administration) because all these factors can affect the
postoperative platelet functions.
The platelet counts before and after surgical intervention
were similar and comparable in both groups (Figure 1). There
was a trend toward a lower platelet count in the on-pump
group (because of hemodilution), but there was no significant
difference between groups. Platelet counts recovered to the
preoperative values on day 5 and exceeded the preoperative
values in both groups on day 30.
Expression of P-selectin on the surface of platelets was
comparable in both groups before the operation and on day
30 (Figure 2). In the off-pump group a significant increase
TABLE 1. Patients' characteristics
On–pump
CABG (n 5 40)
Off–pump
CABG (n 5 40)
P
value
Age (y) 64 6 11 68 6 9 .11
Male sex (%) 82 77 .52
Previous MI (%) 40 50 .31
Hypertension (%) 65 63 .47
Diabetes (%) 35 28 .30
Previous stroke (%) 3 5 1.0
Hyperlipidemia (%) 67 55 .73
Smoking (%) 20 13 .13
Aspirin withdrawal (d) 9 6 2 9 6 4 .98
Quantitative data are expressed as means 6 standard deviation. MI, Myo-
cardial infarction.tober 2008
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Pof expression was recorded on day 2 in comparison with the
preoperative values (P5 .02), and on days 2 and 5, a signif-
icantly higher expression of P-selectin was recorded com-
pared with that seen in the on-pump group (P 5 .004 on
day 2 and P 5 .005 on day 5).
AA-induced platelet aggregation was similar in both
groups before the operation (Figure 3). Immediately after
the operation, platelet aggregation decreased significantly
in both groups compared with the preoperative values, and
only at that time was there a significant difference between
the groups (P 5 .04). On day 2 after the operation, despite
the administration of aspirin, both groups showed an increase
in platelet aggregation of greater than the values from day 1,
Figure 1. Platelet counts. Platelet counts in the off-pump and on-
pump groups at different time points. In the on-pump group there is
a tendency toward lower platelet counts because of extracorpo-
real circulation. No statistically significant differences were
found between the groups at any time points. Data are expressed
as medians with 95% confidence intervals. preOP, Preoperative;
postOP, postoperative.
TABLE 2. Perioperative and postoperative data
On–pump
group (n 5 40)
Off–pump
group (n 5 40)
P
value
No. of grafts 2.4 6 0.6 1.9 6 0.7 ,.01
CPB time (min) 49 6 13
Crossclamp time (min) 27 6 6
Heparin dose (IU 3 1000) 28.5 6 8.5 8 6 5 ,.001
Protamine dose (mg) 440 6 42 150 6 65 ,.001
ACT (s)
Before operation 142 6 31 139 6 36 .52
End of operation 128 6 8 129 6 9 .67
24-h Blood loss (mL) 870 6 404 660 6 364 .03
FFP (% of patients) 35 28 .30
PRBC (% of patients) 43 37 .28
Quantitative data expressed as means 6 standard deviation. CPB, Cardio-
pulmonary bypass; IU, international unit; ACT, activated clotting time; FFP,
fresh frozen plasma; PRBC, packed red blood cells.The Journal of Thorwhich was higher in the off-pump group. On day 5 after the
operation, both groups showed a decrease in platelet aggrega-
tion in comparison with values from day 2, and in the
off-pump group the decrease in aggregation was much
more significant. On day 30 after the operation, inhibition
of platelet aggregation was almost the same in both groups
and reached highly effective values.
Platelet activity and AA aggregability in 4 excluded
patients with perioperative and postoperative MI are shown
in Figure 4.
Finally, there was no statistically significant relationship
between P-selectin expression and AA aggregability
(R5 0.15 and P5 .34). No significant relationship was noted
between changes in 24-hour blood loss and in the preopera-
tive, postoperative, and day 1 values of AA platelet aggreg-
ability (R 5 0.10 and 0.20 and R 50.14) and similarly
between 24-hour blood loss and P-selectin expression
(R 5 0.24 and 0.11 and R 5 0.16).
Discussion
Our study compared early and late postoperative platelet ac-
tivity between the off-pump and on-pump CABG groups.
Platelet activity, as determined by P-selectin expression,
was significantly higher in the off-pump group on day 2 in
comparison with the preoperative values and on days 2 and
5 and in comparison with values in the on-pump group. On
day 30, there was no difference between the groups and in
comparison with preoperative values.
In the available literature there are few and conflicting
data concerning changes in platelet activity after cardiac sur-
gery.8-11,18-21 Therefore the interpretation of our results is not
easy. The activation of platelets could be related only to the
process of healing and to the changes in hemostasis, which
are usually present in the early postoperative period. Higher
platelet activity in off-pump surgery can be a ‘‘normal’’ state
in the postoperative process of hemostasis restitution after
a major operation. In contrast, this condition could be im-
paired in on-pump surgery due to hemostasis dysfunction
caused by an extracorporeal circuit and other factors (eg, oxy-
genator, cardioplegia solution, hypothermia, thrombin, hepa-
rin, and protamine). However, some recent studies have
indicated that the changes in hemostasis in terms of its in-
crease (procoagulant state) could really exist after off-pump
surgery. For example, Lo and colleagues4 and Quigley and
associates5 describe that in off-pump surgery the response
of the coagulation system (platelets were not studied) in-
creased in the later period after the operation (in 20 to 96
hours or in 72 hours) in comparison with that after on-
pump surgery. It is not clear from the published studies
whether platelets participate in this procoagulant state.
Even though the role of platelets in this process has been
questioned by some authors, with regard to the complexity
of the hemostasis process, including interactions between
the coagulation system of blood proteins and platelets, it isacic and Cardiovascular Surgery c Volume 136, Number 4 1057
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CSPFigure 2. Platelet antigen CD62P (P-selectin) expression between the off-pump and on-pump groups. In the off-pump
group expression of P-selectin significantly increased on day 2 in comparison with the preoperative values and
remained significantly higher on days 2 and 5 in comparison with values in the on-pump group. Data are expressed
as medians with 95% confidence intervals (A) and as percentage change from baseline (B). preOP, Preoperative;
postOP, postoperative. *P 5 .004 between off-pump and on-pump groups. **P 5 .005 between off-pump and
on-pump groups.very probable that platelets take part in this process.18 Ac-
cording to our results, platelets could play an important
role in this state. Very few studies can be found in the avail-
able literature that would provide a comparison with our re-
sults by means of their methodology. A recently published
study by Ballotta and coworkers8 also described changes in
platelet activity (P-selectin and Annexin-V) but only very
early after surgical intervention (2 hours). Similar to our
study, it recorded an increase in P-selectin expression in
both groups in the early postoperative period, but this in-
crease was significantly higher in on-pump surgery compared
with off-pump surgery. No comparisons in the later postoper-
ative period were described. Parolari and associates20 did not
find any significant changes in P-selectin expression between
off-pump and on-pump CABG on days 4, 8, and 30 after the
operation, although they had a lower number of patients.
Higher platelet activity is associated with thrombotic com-
plications in patients with coronary artery disease, and can be
used to predict patients at risk of an adverse cardiovascular
event (eg, reappearance of ischemia and the need for reinter-
vention after percutaneous coronary intervention).22-24 It is
not clear whether higher platelet activity can be associated
with early bypass graft failure or whether it can contribute
to negative clinical outcomes after bypass surgery.19 Al-
though it is not possible to make a valid conclusion from
the platelet tests performed in our 4 patients with a postoper-
ative MI (our study was not designed for this objective), at
least 2 of them had significantly higher preoperative values
of P-selectin. However, according to Poston and co-
workers,18 what could cause graft failure is not the platelet
activation itself but its interaction with coagulation cascade
reactions, which appear on the surface of activated platelets
Figure 3. Arachidonic acid–induced platelet aggregation in the off-pump versus on-pump groups at different time
points. Data are expressed as medians with 95% confidence intervals (A) and as percentage change from baseline
(B). preOP, Preoperative; postOP, postoperative. *P 5 .04 between off-pump and on-pump groups.1058 The Journal of Thoracic and Cardiovascular Surgery c October 2008
Bednar et al Cardiopulmonary Support and PhysiologyFigure 4. Platelet antigen CD62P (P-selectin) expression and arachidonic acid–induced platelet aggregation in 4
patients with perioperative or postoperative myocardial infarction. preOP, Preoperative; postOP, postoperative.CS
Pat the site of endothelial injury. Further studies are needed to
clarify the complexity of these relations.
Apart from the assessment of platelet activity by means of
P-selectin expression, we also focused on the evaluation of
platelet aggregation after repeated administration of aspirin
early after bypass surgery. It must be emphasized that P-se-
lectin expression and platelet aggregation do not correlate to-
gether, which has been proved not only in our study but also
in the available literature.25 Each of these factors describes
something else in platelet function and activation. AA-in-
duced platelet aggregation measured by means of light trans-
mission aggregometry is today considered to be a reference
method to evaluate aspirin efficacy, and its results provided
very interesting findings.26 On postoperative day 2, after pre-
vious reduction in aggregability caused by heparin and CPB
(in the on-pump group), platelet aggregation increased unex-
pectedly and even more in the off-pump group. The increase
in aggregability was recorded despite the administration of 2
doses of aspirin. Thus we can assume that platelet function is
restored, but the inhibition effect of aspirin is still insufficient.
This condition is more expressed in less dysfunctional plate-
lets in the off-pump group. Unfortunately, changes in platelet
aggregation were not measured on postoperative days 3 and 4
according to the study protocol. Therefore the expected inhi-
bition effect of aspirin occurs approximately between postop-
erative days 3 and 5. We can speculate whether the less
dysfunctional platelets after off-pump surgery are, in con-
trast, more sensitive to the inhibition effect of aspirin in the
later postoperative period, as the values of AA-induced plate-
let aggregation indicated on postoperative day 5. InsufficientThe Journal of Thoraplatelet inhibition early after bypass surgery was also de-
scribed by Zimmermann and colleagues,27 who measured
levels of thromboxane B2 in plasma after oral administration
of aspirin. Similarly, Poston and coworkers19 recorded
a significant increase in platelet resistance to aspirin effect
in off-pump patients with early graft thrombosis. Aspirin in-
sufficiency (resistance) early after bypass surgery is therefore
a real problem to which more attention must be paid. The
clinical effect of all these findings is also supported by the
fact that the early postoperative period is extremely risky
for early graft failure because of thrombosis.28 There arises
a question whether modification or intensification of the
dose regimen of aspirin or different antiplatelet strategies
after off-pump and on-pump bypass surgery could lead to
a more effective inhibition of aggregation with a minimum
influence on postoperative bleeding and thus possibly to bet-
ter clinical outcomes. Our results also support considerations
about dual therapy with aspirin and clopidogrel, when clopi-
dogrel, unlike aspirin, inhibits not only platelet aggregability
but also P-selectin expression.29 However, to answer these
and other questions, we need additional studies.
Study Limitations
Our trial includes a low number of patients, and it will be ne-
cessary to confirm or disprove our findings in future studies
in a larger number of patients with a possible use of other sen-
sitive markers of platelet activity and methods of measure-
ment of aspirin efficacy. Our patients form a group of
selected patients because our objective was to compare the
influence of 2 different operative methods on the definedcic and Cardiovascular Surgery c Volume 136, Number 4 1059
Cardiopulmonary Support and Physiology Bednar et al
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sibility of obtaining different results in acute patients whose
platelet activity might have already been primarily affected.
Also, by excluding the patients with postoperative MI, the
authors do not ignore the intention-to-treat rule, but they
try to prevent the distortion of results by those patients who
might primarily show higher postoperative platelet activity
as a consequence of MI. Furthermore, we have to take into
account different doses of heparin/protamine in both types
of operation and their possible influence on platelet dysfunc-
tion. A certain limitation to the interpretation of the results is
also caused by the fact that antifibrinolytics were not used.
However, a distortion of the results could be caused by using
a different dose in the off-pump and on-pump groups. Also,
the administration of a 200-mg dose of aspirin does not cor-
respond with standard guidelines, but this dose is usual in the
Czech Republic because 325 mg of aspirin is not registered in
our country.
Conclusions
The PRAGUE 11–CABARET trial is the first prospective
randomized study that demonstrates a significantly higher
platelet activity in off-pump compared with on-pump
CABG in the early postoperative period by means of a gen-
erally accepted marker of platelet activity. It also proves
that aspirin insufficiency is a real problem that is present
in the early postoperative period, and it is probably ex-
pressed in different ways between the off-pump and on-
pump CABG operations.
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